HomeCompareMKGAF vs PFE

MKGAF vs PFE: Dividend Comparison 2026

MKGAF yields 2.04% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MKGAF wins by $88.6K in total portfolio value
10 years
MKGAF
MKGAF
● Live price
2.04%
Share price
$122.45
Annual div
$2.50
5Y div CAGR
52.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$138.2K
Annual income
$57,634.11
Full MKGAF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — MKGAF vs PFE

📍 MKGAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMKGAFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MKGAF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MKGAF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MKGAF
Annual income on $10K today (after 15% tax)
$173.61/yr
After 10yr DRIP, annual income (after tax)
$48,988.99/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, MKGAF beats the other by $26,669.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MKGAF + PFE for your $10,000?

MKGAF: 50%PFE: 50%
100% PFE50/50100% MKGAF
Portfolio after 10yr
$93.9K
Annual income
$41,946.42/yr
Blended yield
44.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

MKGAF
No analyst data
Altman Z
2.6
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MKGAF buys
0
PFE buys
0
No recent congressional trades found for MKGAF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMKGAFPFE
Forward yield2.04%6.13%
Annual dividend / share$2.50$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR52.7%13.2%
Portfolio after 10y$138.2K$49.6K
Annual income after 10y$57,634.11$26,258.71
Total dividends collected$109.9K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MKGAF vs PFE ($10,000, DRIP)

YearMKGAF PortfolioMKGAF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,012$311.88$9,153$693.39+$1.9KMKGAF
2$12,273$490.13$8,593$849.25+$3.7KMKGAF
3$13,912$779.56$8,336$1,066.78+$5.6KMKGAF
4$16,146$1,261.05$8,437$1,384.80+$7.7KMKGAF
5$19,365$2,088.77$9,013$1,875.40+$10.4KMKGAF
6$24,296$3,575.17$10,306$2,680.72+$14.0KMKGAF
7$32,398$6,401.21$12,820$4,101.38+$19.6KMKGAF
8$46,847$12,181.47$17,673$6,826.70+$29.2KMKGAF
9$75,264$25,137.47$27,543$12,591.86+$47.7KMKGAF
10$138,167$57,634.11$49,560$26,258.71+$88.6KMKGAF

MKGAF vs PFE: Complete Analysis 2026

MKGAFStock

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Full MKGAF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this MKGAF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MKGAF vs SCHDMKGAF vs JEPIMKGAF vs OMKGAF vs KOMKGAF vs MAINMKGAF vs JNJMKGAF vs MRKMKGAF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.